Cleveland BioLabs Company Profile (NASDAQ:CBLI)

Analyst Ratings

Consensus Ratings for Cleveland BioLabs (NASDAQ:CBLI) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Cleveland BioLabs (NASDAQ:CBLI)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Cleveland BioLabs (NASDAQ:CBLI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/16/2016Q116($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/22/2016Q4($0.03)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.31)$415.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215($1.12)$562.10 million$329.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115($1.14)$1.33 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2015Q114($1.02)$3.87 million$1.39 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q2($0.09)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014($0.05)($0.03)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2014Q413($0.12)($0.01)$1.74 million$3.87 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2013Q313($0.14)($0.09)$1.61 million$1.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2013Q2 2013($0.16)($0.07)$1.48 million$1.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013($0.17)($0.22)$1.73 million$1.37 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q312($0.02)($0.30)$23.87 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cleveland BioLabs (NASDAQ:CBLI)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Cleveland BioLabs (NASDAQ:CBLI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cleveland BioLabs (NASDAQ:CBLI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/25/2015Randy S SaluckDirectorBuy1,891$3.42$6,467.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2013Paul E DicorletoDirectorBuy6,210$1.61$9,998.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2013Randy S SaluckDirectorBuy3,500$1.60$5,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2013James AntalDirectorBuy3,700$1.56$5,772.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2012James AntalDirectorBuy2,316$2.60$6,021.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cleveland BioLabs (NASDAQ:CBLI)
DateHeadline
07/22/16 03:22 PMCLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal Officers -
07/21/16 05:05 AMCLEVELAND BIOLABS INC Files SEC form 8-K/A, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta -
07/19/16 11:08 AMETF’s with exposure to Cleveland BioLabs, Inc. : July 19, 2016 -
07/12/16 03:25 PMCLEVELAND BIOLABS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stand -
07/12/16 08:13 AMCleveland BioLabs Announces Board Resignations - [at noodls] - BUFFALO, NY--(Marketwired - Jul 12, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that Board Chair Richard McGowan and Audit Committee Chair James Antal resigned from the company's Board ...
06/22/16 07:51 AMServices Sector Daily Watch: Winners & Losers
05/17/16 11:26 AMCleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/16/16 01:01 PMFriday Morning’s Top Movers – UNIS, HTGM, ORMP, NVDA, CETX, CBLI, RUN - The company is -10.59 pct year-to-date, and -45.64 pct during the past four quarters. Cleveland BioLabs Inc (CBLI) traded at $2.31 + 0.2066 (9.84 pct) on 890 total stock volume. The company is -33.91 pct year-to-date, and +13.61 pct during the past four ...
05/16/16 07:02 AMCleveland BioLabs Reports First Quarter 2016 Financial Results and Development Progress - [at noodls] - BUFFALO, NY--(Marketwired - May 16, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the first quarter ended March 31, 2016. Cleveland BioLabs ...
05/12/16 01:40 PM22nd Century to begin cannabis research at new medical campus labs -
05/06/16 04:55 PMCLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibit -
04/15/16 02:05 PMCLEVELAND BIOLABS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
04/04/16 06:37 AMCleveland BioLabs Announces Webcast of Annual Meeting - [at noodls] - BUFFALO, NY--(Marketwired - Apr 4, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company will webcast its 2016 Annual Meeting of Stockholders on April 14, 2016 at its headquarters ...
03/17/16 01:04 AMGLPG Awaits SAPHIRA Data, VTAE Vaults, CBLI Hits A Snag - CERS closed Wednesday' trading at $5.79, down 3.34%. It looks like the progress of regulatory review of Cleveland BioLabs Inc.'s (CBLI) pre-Emergency Use Authorization submission for Entolimod as a radiation countermeasure is going to be delayed.
03/16/16 01:50 PMCLEVELAND BIOLABS INC Files SEC form 8-K, Other Events -
03/16/16 01:00 PMCleveland BioLabs Provides Update on Pre-EUA Review of Entolimod as Radiation Countermeasure - [Marketwired] - Cleveland BioLabs, Inc. today announced an update on the regulatory review of its pre-Emergency Use Authorization submission for entolimod as a radiation countermeasure following the receipt of minutes ...
03/08/16 10:42 AMHottest Services Stocks Now – CAI NEWT INST MOBL - Instructure Inc (INST): INST stock is down 0.47% today. Mobileiron Inc (MOBL): MOBL stock is up 1.98% today. Cleveland Biolabs (CBLI): CBLI stock is down 0.85% today. Weibo Corp (WB): WB stock is up 1.12% today. Care.Com Inc (CRCM): CRCM stock is up 0.78% ...
02/23/16 04:04 PMCLEVELAND BIOLABS INC Files SEC form 10-K, Annual Report -
02/22/16 09:35 AMCLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition -
02/22/16 06:30 AMCleveland BioLabs Reports 2015 Financial Results and Development Progress - [Marketwired] - Cleveland BioLabs, Inc. today reported financial results and development progress for the fourth quarter and year ended December 31, 2015.
02/18/16 05:31 PMCleveland BioLabs, Inc. (CBLI) - Cleveland BioLabs, Inc., a biopharmaceutical company, focuses on developing pharmaceuticals designed to address diseases with unmet medical need. Its lead drug candidate is Entolimod, a Toll-like receptor 5 (TLR5) agonist, which is developing as a ...
02/09/16 09:47 AMHottest Services Stocks Now – ADUS SREV EBIX CBLI - Servicesource International In (SREV): SREV stock is up 4.62% today. Ebix Inc (EBIX): EBIX stock is up 3.77% today. Cleveland Biolabs (CBLI): CBLI stock is up 1.47% today. SP Plus Corporation (SP): SP stock is up 2.71% today. Datawatch Corp (DWCH): DWCH ...
02/09/16 09:47 AMCleveland Biolabs (CBLI) Says Entolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T cell Axis - Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Roswell Park Cancer Institute (RPCI) today announced the publication of studies elucidating immunotherapeutic mechanisms through which entolimod suppresses metastasis. The data were published in Proceedings of the ...
02/09/16 06:30 AMEntolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T cell Axis in Studies by Cleveland BioLabs and Roswell Park Cancer Institute - [Marketwired] - Cleveland BioLabs, Inc. and Roswell Park Cancer Institute today announced the publication of studies elucidating immunotherapeutic mechanisms through which entolimod suppresses metastasis. The data were ...
02/02/16 07:00 AMCleveland BioLabs Announces Start of Colorectal Cancer Study of Entolimod in Russian Federation - [Marketwired] - Cleveland BioLabs, Inc. today announced the initiation of a Phase 2, single-blind, randomized, placebo-controlled clinical study of the safety and tolerability of entolimod as a neo-adjuvant therapy in ...
01/26/16 06:49 AMCleveland BioLabs Announces Start of Phase 2 Study of CBLB612 in Russian Federation - [at noodls] - BUFFALO, NY--(Marketwired - Jan 26, 2016) - Cleveland BioLabs, Inc. (: ) today announced the start of dosing in a Phase 2, randomized, placebo-controlled clinical study of CBLB612 as myelosuppressive prophylaxis ...
01/22/16 02:25 PMCleveland BioLabs Gets Orphan Status for Entolimod in EU -
01/21/16 06:45 AMCleveland BioLabs Attains Orphan Drug Status From the EMA for Entolimod as a Radiation Countermeasure - [at noodls] - BUFFALO, NY--(Marketwired - Jan 21, 2016) - Cleveland BioLabs, Inc. (: ), today announced that entolimod has been granted orphan drug status by the European Medicines Agency (EMA) for treatment of acute ...
01/21/16 06:30 AM7:30 am Cleveland Biolabs announces that entolimod has been granted orphan drug status by the EMA for treatment of acute radiation syndrome -
12/24/15 12:04 PMCLEVELAND BIOLABS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Defin -
12/22/15 06:40 AMCleveland BioLabs and Rusnano Make Additional Investments in Panacela - [at noodls] - BUFFALO, NY--(Marketwired - Dec 22, 2015) - Cleveland BioLabs, Inc. (: ) today announced that through a series of transactions and in cooperation with Open Joint Stock Company RUSNANO (Rusnano) it has ...
12/16/15 12:16 PMCleveland BioLabs, Inc. Earnings Analysis: Q3, 2015 By the Numbers -
12/14/15 06:30 AMEntolimod Shown to Suppress Liver Metastases in Model of Ocular Melanoma in Collaborative Study by Cleveland BioLabs, Emory University and Roswell Park Cancer Institute - [Marketwired] - Cleveland BioLabs, Inc. , Emory University and Roswell Park Cancer Institute today announced the publication of a study in Oncotarget demonstrating the ability of entolimod to suppress liver metastases ...
12/08/15 12:17 PMCLEVELAND BIOLABS INC Financials -
11/30/15 07:00 AMCleveland BioLabs Announces Expanded U.S. Patent Protection for Entolimod - [at noodls] - Cleveland BioLabs Announces Expanded U.S. Patent Protection for Entolimod
11/09/15 03:17 PMCLEVELAND BIOLABS INC Files SEC form 10-Q, Quarterly Report -
11/05/15 06:40 AMCleveland BioLabs Reports Third Quarter 2015 Financial Results and Development Progress - [at noodls] - Cleveland BioLabs Reports Third Quarter 2015 Financial Results and Development Progress
11/05/15 06:31 AMCLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh -
11/05/15 06:07 AMQ3 2015 Cleveland Biolabs Inc Earnings Release - Time Not Supplied -
10/27/15 07:15 AMCleveland BioLabs to Report Third Quarter 2015 Financial Results on November 5 - [at noodls] - Cleveland BioLabs to Report Third Quarter 2015 Financial Results on November 5

Social

About Cleveland BioLabs

Cleveland BioLabs logoCleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company's programs are focused developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is entolimod, an immuno-stimulatory agent, which the Company is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. It also has an additional clinical-stage program and multiple projects in different stages of preclinical drug development. Its products include Entolimod, CBLB612, CBL0137 and Mobilan. Entolimod is a toll-like receptor 5 (TLR5). CBLB612 is a compound-based upon a natural activator of another tissue-specific component of the immune system. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CBLI
  • CUSIP:
Key Metrics:
  • Previous Close: $2.41
  • 50 Day Moving Average: $2.6474
  • 200 Day Moving Average: $2.8307
  • P/E Ratio: N/A
  • P/E Growth: 0.0000
  • Market Cap: $27.17M
  • Beta: 1.01
  • Current Year EPS Consensus Estimate: $-0.16 EPS
  • Next Year EPS Consensus Estimate: $-0.48 EPS
Additional Links:
Cleveland BioLabs (NASDAQ:CBLI) Chart for Monday, July, 25, 2016